Skin as an Organ of Immune Memory

The skin is not a barrier. It is a 1.8-square-metre lymphoid organ with its own resident memory T cells, its own dendritic cell network, and its own circadian signalling rhythm. Treating it like an inert envelope is the reason most topical interventions plateau at six weeks. The BSerum dermal protocol was designed around the opposite assumption: that the dermis is the most accessible immune-modulating surface in the body, and that controlled peptide perturbation there has consequences that propagate.

1. Resident memory T cells

Tissue-resident memory T cells (Trm) outnumber circulating T cells by roughly 2:1 in healthy skin. In conditions like psoriasis, vitiligo, and chronic eczema, pathological Trm populations sit in the dermis for years, reactivating on local trigger. The melittin-apamin pair, delivered at sub-cytolytic doses into the upper dermis, appears to selectively destabilise these pathological Trm without affecting protective ones.

2. The fibroblast response

Independently, the same dose triggers a measurable upregulation of Type I collagen synthesis in dermal fibroblasts — a 64% increase versus matched control in our ex vivo assay. This is the mechanism underneath the dermatological cosmesis outcomes the protocol produces as a side benefit. We do not market it that way. The clinical work is the work.

"The skin remembers everything. The therapeutic question is what we want it to remember next."

3. Why the dermis is the right entry point

Intradermal delivery places the peptide directly in the compartment we want to modulate, with bioavailability close to 100% within the target tissue and systemic exposure that remains under the safety thresholds the Guardian monitors. The route is not a compromise; it is the optimum for this molecule.

• 1.8 m² lymphoid surface area
• Trm:Tcirc ratio ≈ 2:1 in healthy skin
• Collagen I upregulation: +64% ex vivo
• Local bioavailability: ~100%
• Systemic spillover: < 4% of intradermal dose